Carregant...

Establishing a reasonable price for an orphan drug

BACKGROUND: This paper addresses the question of what a reasonable price for an orphan drug is. The research proposes a way to adjust an established payer/HTA body incremental cost-effectiveness threshold (CET) to take account of differences in patient populations and costs of research and developme...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cost Eff Resour Alloc
Autors principals: Berdud, Mikel, Drummond, Michael, Towse, Adrian
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7472708/
https://ncbi.nlm.nih.gov/pubmed/32908456
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-020-00223-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!